EAU 2014 - Poster: Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase 3 trials

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Michael Stöckle,¹ Thomas Flaig,² Carsten H. Ohlmann,¹ Howard I. Scher,³ Johann S. de Bono,⁴ Dana E. Rathkopf,³ Charles J. Ryan,⁵ Thian Kheoh,⁶ Jinhui Li,⁷ Mary B. Todd,⁸ Thomas W. Griffin,⁶ Arturo Molina,⁹ and Karim Fizazi¹⁰ at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

¹Saarland University, Homburg/Saar, Germany; ²University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, CO, USA; ³Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; ⁴The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK; ⁵Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA; ⁶Janssen Research & Development, Los Angeles, CA, USA; ⁷Janssen Research & Development, Raritan, NJ, USA; ⁸Janssen Global Services, Raritan, NJ, USA; ⁹Janssen Research & Development, Menlo Park, CA, USA; ¹⁰Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Click HERE to read an exclusive report by a UroToday medical writer